mechanism of action of glp-1 receptor agonist GLP1 Agonists—Effects beyond Obesity and Diabetes Mechanism of action of GLP-1
Description
doi: 10.1371/journal.pone.0270143
It's helping sleep, it's mood stability
As illustrated in Figure 2, pooled analyses of cardiovascular outcome trials have demonstrated that GLP-1 RAs reduce major adverse cardiovascular events (MACEs) by 14% (HR = 0.86, 95% CI 0.790.94) in patients with type 2 diabetes, with additional significant benefits including 13% reduction in cardiovascular death, 16% reduction in nonfatal stroke, and 10% reduction in hospitalization for heart failure [85]
Liraglutide, a GLP-1 agonist, as a new adjunct treatment in Hailey-Hailey disease: a case report
Novel foods authorisation guidance
